Literature DB >> 25923596

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.

Juergen K Rockstroh, Vicente Soriano, Frank Plonski, Meena Bansal, Gerd Fätkenheuer, Catherine B Small, David M Asmuth, Gilles Pialoux, Geoffrey Mukwaya, Shyla Jagannatha, Jayvant Heera, Juan A Pineda.   

Abstract

BACKGROUND: One of the more clinically relevant co-morbidities in HIV-infected patients is the development of progressive liver disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV). In addition, hepatotoxicity has been observed with prolonged use of antiretroviral agents.
OBJECTIVE: To evaluate the hepatic safety of maraviroc in combination with other antiretroviral agents in HIV-1-infected subjects co-infected with HCV and/or HBV.
METHODS: In this 148-week randomized, double-blind, placebo-controlled, multicentre study (NCT01327547), subjects received maraviroc twice daily (n = 70) or placebo (n = 67) in combination with other antiretroviral agents. PRIMARY ENDPOINT: the percentage at week 48 of subjects with Grade 3 and Grade 4 ALT abnormalities, defined as >5 ×  upper limit of normal (ULN) if baseline ALT ≤ ULN or >3.5 ×  baseline if baseline ALT>ULN in the maraviroc versus the placebo arm.
RESULTS: At week 48, one subject in each group had met the primary endpoint definition. No subjects met protocol-defined liver stopping criteria and there were no cases of Hy's law or treatment-related hepatobiliary serious adverse events. No significant difference in change from baseline in enhanced liver fibrosis or hepatic elastography was observed between groups. Treatment-related hepatobiliary adverse events were reported in one and two subjects receiving maraviroc and placebo, respectively; discontinuations due to treatment-related AEs occurred in four and two subjects receiving maraviroc and placebo, respectively; two deaths were reported in the placebo group.
CONCLUSIONS: The use of maraviroc does not increase hepatotoxicity in HIV-1-infected subjects co-infected with HCV and/or HBV through 48 weeks of treatment.

Entities:  

Keywords:  HIV,; Hepatitis B,; Hepatitis C,; Hepatotoxicity,; Maraviroc

Mesh:

Substances:

Year:  2015        PMID: 25923596     DOI: 10.1179/1528433614Z.0000000011

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  3 in total

1.  Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone.

Authors:  Daniel Bradshaw; Yvonne Gilleece; Sumita Verma; Iga Abramowicz; Stephen Bremner; Nicky Perry
Journal:  BMJ Open       Date:  2020-07-06       Impact factor: 2.692

2.  Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

Authors:  Carlo Giaquinto; Muthuhadini Patience Mawela; Kulkanya Chokephaibulkit; Marinella Della Negra; Ismail Haroon Mitha; Jan Fourie; Annie Fang; Elna van der Ryst; Srinivas Rao Valluri; Manoli Vourvahis; Rebecca Yanhui Zhang-Roper; Charles Craig; Lynn McFadyen; Andrew Clark; Jayvant Heera
Journal:  Pediatr Infect Dis J       Date:  2018-05       Impact factor: 2.129

3.  CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.

Authors:  Jason T Blackard; Ling Kong; Susan D Rouster; Rebekah Karns; Paul S Horn; Shyam Kottilil; M Tarek Shata; Kenneth E Sherman
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.